Governance evidence
What agencies reported about the OMB M-25-21 minimum practices for high-impact AI. This is a disclosure analysis, not an audit, a compliance finding or an official assessment. An unanswered question is missing evidence, not evidence that a safeguard is absent.
Practice-by-practice evidence
Denominator: 6 records · use cases designated high-impact| Practice | In scope | In place | In progress | Not in place | N/A | Precluded or waived | Other | No answer | Answered | In place of applicable |
|---|---|---|---|---|---|---|---|---|---|---|
| Pre-deployment testing | 6 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 100% | 0% of 6 |
| AI impact assessment | 6 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 100% | 0% of 6 |
| Independent review | 6 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 100% | 0% of 6 |
| Ongoing monitoring | 6 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 100% | 0% of 6 |
| Operator training | 6 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 100% | 0% of 6 |
| Fail-safe | 6 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 100% | 0% of 6 |
| Appeal process | 6 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 100% | 0% of 6 |
| User and public consultation | 6 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 100% | 0% of 6 |
Answered = records with any answer ÷ records in scope. In place of applicable = reported in place ÷ (in scope minus not applicable, precluded and waived). Unanswered records stay in that denominator, so the rate is a lower bound on reported evidence, not an estimate of real practice.
| Testing | Impact assess. | Indep. review | Monitoring | Training | Fail-safe | Appeal | Consultation | n | |
|---|---|---|---|---|---|---|---|---|---|
| DOJ | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 6 |
Hatched cells: the agency answered nothing for that practice, so there is no evidence either way. Compare agencies with care: each agency is one reporting unit, and portfolios differ in size and type.
Records requiring further investigation
6 records with at least one practice unanswered or in progressOpen in explorer| Use case | Stage | Test | AIA | Review | Monitor | Train | Fail-safe | Appeal | Consult |
|---|---|---|---|---|---|---|---|---|---|
| ASCVD (Atherosclerotic Cardiovascular Disease) Risk Estimator DOJ · DOJ-0142 | Deployed | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress |
| Automated Medication Dispensing Cabinet DOJ · DOJ-0143 | Deployed | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress |
| Community Treatment Pipeline Screening DOJ · DOJ-0149 | Deployed | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress |
| Medical Claims Adjudication DOJ · DOJ-0156 | Deployed | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress |
| Medical Designations Calculator DOJ · DOJ-0157 | Deployed | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress |
| Psychological Test Interpretation - Pearson Assessments DOJ · DOJ-0161 | Deployed | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress | Reported in progress |
Unanswered analytical questions
Generated from the data; for follow-up with agencies- 6 high-impact use cases are reported as deployed while their AI impact assessment is reported in progress. Was deployment authorised before the assessment was complete?
- 6 high-impact use cases report using PII but give no link to a Privacy Impact Assessment. Is a PIA published elsewhere?
These are questions the inventory raises but cannot answer. They are not findings of non-compliance.